Assetmark Inc. lifted its holdings in shares of Natera, Inc. (NASDAQ:NTRA – Get Rating) by 50.5% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,314 shares of the medical research company’s stock after acquiring an additional 441 shares during the quarter. Assetmark Inc.’s holdings in Natera were worth $58,000 at the end of the most recent quarter.
Other institutional investors and hedge funds also recently modified their holdings of the company. Chartwell Investment Partners LLC increased its position in Natera by 3.6% in the third quarter. Chartwell Investment Partners LLC now owns 33,416 shares of the medical research company’s stock worth $1,464,000 after buying an additional 1,171 shares during the last quarter. Synovus Financial Corp purchased a new stake in Natera in the third quarter worth $1,377,000. Assenagon Asset Management S.A. increased its position in Natera by 45.3% in the third quarter. Assenagon Asset Management S.A. now owns 707,835 shares of the medical research company’s stock worth $31,017,000 after buying an additional 220,668 shares during the last quarter. Allspring Global Investments Holdings LLC purchased a new stake in Natera in the third quarter worth $5,746,000. Finally, Westwood Management Corp IL purchased a new stake in Natera in the third quarter worth $1,126,000. 93.81% of the stock is owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
A number of research firms have issued reports on NTRA. Piper Sandler reissued an “overweight” rating and issued a $70.00 target price on shares of Natera in a research report on Tuesday, January 17th. StockNews.com began coverage on Natera in a report on Wednesday, October 12th. They issued a “sell” rating for the company. Robert W. Baird cut their price target on Natera from $72.00 to $65.00 in a report on Wednesday, November 9th. Credit Suisse Group cut their price target on Natera from $70.00 to $55.00 and set an “outperform” rating for the company in a report on Monday, November 14th. Finally, BTIG Research cut their price target on Natera from $95.00 to $75.00 in a report on Wednesday, November 9th. One analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $81.67.
Natera Price Performance
Natera (NASDAQ:NTRA – Get Rating) last posted its quarterly earnings data on Tuesday, November 8th. The medical research company reported ($1.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.42) by $0.17. The company had revenue of $210.64 million during the quarter, compared to analyst estimates of $208.31 million. Natera had a negative return on equity of 109.07% and a negative net margin of 70.34%. On average, research analysts expect that Natera, Inc. will post -5.64 EPS for the current fiscal year.
Insider Activity at Natera
In related news, CEO Steven Leonard Chapman sold 8,212 shares of Natera stock in a transaction on Tuesday, January 3rd. The stock was sold at an average price of $39.55, for a total transaction of $324,784.60. Following the completion of the sale, the chief executive officer now owns 93,831 shares of the company’s stock, valued at $3,711,016.05. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other Natera news, CFO Michael Burkes Brophy sold 915 shares of Natera stock in a transaction dated Wednesday, December 28th. The stock was sold at an average price of $39.84, for a total transaction of $36,453.60. Following the completion of the sale, the chief financial officer now owns 91,350 shares of the company’s stock, valued at $3,639,384. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Steven Leonard Chapman sold 8,212 shares of Natera stock in a transaction dated Tuesday, January 3rd. The stock was sold at an average price of $39.55, for a total value of $324,784.60. Following the sale, the chief executive officer now directly owns 93,831 shares of the company’s stock, valued at approximately $3,711,016.05. The disclosure for this sale can be found here. Over the last quarter, insiders sold 33,144 shares of company stock valued at $1,311,749. Company insiders own 10.27% of the company’s stock.
Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.
- Get a free copy of the StockNews.com research report on Natera (NTRA)
- CVS Health is Growing into an Integrated Healthcare Organization
- Is C3.ai Stock a ChatGPT Artificial Intelligence Play?
- NVIDIA Outlook Improving: Watchlist Candidate for 2023
- Which Wireless Stock Should You Buy in 2023?
- Is Virgin Galactic Stock Preparing for Lift-Off?
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.